LEADER 04625nam 2200565 450 001 9910511486903321 005 20170919041041.0 010 $a1-68108-233-0 035 $a(CKB)3710000000627717 035 $a(EBL)4504170 035 $a(MiAaPQ)EBC4504170 035 $a(EXLCZ)993710000000627717 100 $a20160503h20162016 uy 0 101 0 $aeng 135 $aur|n|---||||| 181 $2rdacontent 182 $2rdamedia 183 $2rdacarrier 200 00$aAdvances in cancer drug targets$hVolume 3 /$fAtta-ur-Rahman, editor ; contributors Alain J. P. Alix [and thirty seven others] 210 1$aSharjah, United Arab Emirates :$cBentham Science Publishers,$d2016. 210 4$dİ2016 215 $a1 online resource (278 p.) 225 0 $aAdvances in Cancer Drug Targets,$x2213-9915 ;$vVolume 3 300 $aDescription based upon print version of record. 311 $a1-68108-234-9 320 $aIncludes bibliographical references at the end of each chapters and index. 327 $aCONTENTS; PREFACE ; List of Contributors ; Neutrophil Elastase as a Target in Lung Cancer: the State of the Art ; 1. INTRODUCTION: NEUTROPHIL ELASTASE/?-1ANTITRYPSIN IMBALANCE AS A LINK BETWEEN CHRONIC OBSTRUCTIVE PULMONARY DISEASE AND LUNG CANCER; 2. MULTIFACETED FUNCTIONS OF NEUTROPHIL ELASTASE IN LUNG CANCER; 3. ENDEGNENOUS NEUTROPHIL ELASTASE INHIBITORS; 3.1. Proteinaceous Inhibitors; 3.2. Natural Compounds; 3.2.1. Glycosaminoglycans; 3.2.2. Phenolics; 3.2.3. Triterpenoids ; 3.2.4. Fatty Acids and Peptide Derivatives; 4. DESIGN OF DUAL NEUTROPHIL ELASTASE / MMP INHIBITORS 327 $aDESIGN OF DUAL HNE-MMP INHIBITORSCONCLUDING REMARKS; ADDITIONAL MATERIAL; 1. Molecular Modeling and Molecular Graphics; 2. Ligand and Receptor Preparation; 3. Docking Protocol; CONFLICT OF INTEREST; DISCLOSURE; ACKNOWLEDGEMENTS; ABBREVIATIONS; REFERENCES; Inhibition of Membrane Complement Inhibitor Expression (CD46, CD55, CD59) by siRNA Sensitizes Tumor Cells to Complement Attack ; INTRODUCTION; MATERIALS AND METHODS; Cell Culture; SiRNA Sequences; SiRNA Transfection; Flow Cytometry; Complement-mediated Cytotoxicity Assay (CDC); C3-binding Studies; Real-Time RT-PCR; Statistical Analysis 327 $aRESULTSDesign of siRNAs Specific for CD46, CD55 and CD59; SiRNA-mediated Downregulation of mCRP Expression; siRNA-mediated Augmentation of Tumor Cell Complement Lysis and Opsonization; Time-course of siRNA-induced mCRP Inhibition; Stable Downregulation of CD59 Using an Hairpin siRNA Expression Vector; DISCUSSION; CONFLICT OF INTEREST; DISCLOSURE; ACKNOWLEDGEMENT; ABBREVIATIONS; REFERENCES; Points of Therapeutic Intervention along the Wnt Signaling Pathway in Hepatocellular Carcinoma ; INTRODUCTION; THE WNT SIGNALING PATHWAY; Overview of the Wnt Signaling; The Wnt/?-catenin Pathway 327 $aAberrant Activation of the Wnt/?-catenin Pathway in HCCTARGETING THE WNT/?-CATENIN PATHWAY IN HCC; Targeting the Upstream Components; Endogenous Inhibitors of the Ligand/Receptor Complex; Targeting Wnt Ligands and FZD Receptors ; Targeting the Dishevelled Protein; Cellular Trafficking and Targets; Targeting the ?-catenin Destruction Complex; Targeting the ?-catenin/TCF Transcriptional Complex; Pitfalls in Targeting the Wnt/?-catenin Pathway; CONCLUSIONS AND PERSPECTIVES ; CONFLICT OF INTEREST; DISCLOSURE; ACKNOWLEDGMENT; ABBREVIATIONS; REFERENCES 327 $aCollaboration of Epithelial Mesenchymal Transition and Cancer Stem Cells: Sinister Routes for Chemoresistant Recurrent Ovarian Cancer INTRODUCTION; PATHOLOGY OF OVARIAN CANCER; TRANSITION FROM EPITHELIAL TO MESENCHYMAL PHENOTYPE AND THE PROGRESSION OF CANCER ; EVIDENCE OF EMT IN OVARIAN CANCER; STEM CELLS IN NORMAL OVARIES AND OVARIAN CANCER; SPHERE FORMATION AND THE CANCER STEM CELL PHENOTYPE OF THE OVARY; ASSOCIATION OF EMT AND CSCS: A MERGER FOR POTENTIAL CHEMORESISTANCE IN OVARIAN CANCER 327 $aCisplatin Induced EMT Generates Ovarian Cancer Stem-Like Cells: A Study on the OVCA 433 Cell Line as an Experimental Model 410 0$aAdvances in Cancer Drug Targets 606 $aCancer$xChemotherapy 606 $aDrug targeting 606 $aDrug delivery systems 608 $aElectronic books. 615 0$aCancer$xChemotherapy. 615 0$aDrug targeting. 615 0$aDrug delivery systems. 676 $a616.994061 702 $aRahman$b Atta-ur- 702 $aAlix$b Alain J. P. 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910511486903321 996 $aAdvances in cancer drug targets$92549881 997 $aUNINA LEADER 02435oam 2200493zu 450 001 9910375932703321 005 20210807001955.0 035 $a(CKB)3170000000002273 035 $a(SSID)ssj0001139264 035 $a(PQKBManifestationID)11630708 035 $a(PQKBTitleCode)TC0001139264 035 $a(PQKBWorkID)11183839 035 $a(PQKB)11676795 035 $a(WaSeSS)IndRDA00013912 035 $a(Association for Computing Machinery)10.1145/1028976 035 $a(EXLCZ)993170000000002273 100 $a20160829d2004 uy 101 0 $aeng 135 $aur||||||||||| 181 $ctxt 182 $cc 183 $acr 200 10$aOOPSLA 2004 : conference proceedings : 19th annual ACM Conference on Object-Oriented Programming, Systems, Languages, and Applications : October 24-28, 2004 : Vancouver Convention & Exhibition Centre, Vancouver, British Columbia, Canada 210 31$a[Place of publication not identified]$cACM$d2004 215 $a1 online resource (450 pages) 225 1 $aACM Conferences 300 $aBibliographic Level Mode of Issuance: Monograph 311 $a1-58113-831-8 410 0$aACM Conferences 517 1 $aObject-Oriented Programming, Systems, Languages, and Applications 2004 :$econference proceedings : 19th annual Association for Computing Machinery Conference on Object-Oriented Programming, Systems, Languages, and Applications : October 24-28, 2004, Vancouver Convention and Exhibition Centre, Vancouver, British Columbia, Canada 517 1 $aProceedings of the 19th annual ACM SIGPLAN Conference on Object-Oriented Programming, Systems, Languages, and Applications 517 1 $aOOPSLA '04 ACM SIGPLAN Object Oriented Programming Systems and Applications Conference, Vancouver, Canada - October 24 - 28, 2004 606 $aEngineering & Applied Sciences$2HILCC 606 $aComputer Science$2HILCC 615 7$aEngineering & Applied Sciences 615 7$aComputer Science 700 $aVlissides$b John$065850 712 02$aACM Sigsoft 712 02$aACM Special Interest Group on Programming Languages 801 0$bPQKB 906 $aBOOK 912 $a9910375932703321 996 $aOOPSLA 2004 : conference proceedings : 19th annual ACM Conference on Object-Oriented Programming, Systems, Languages, and Applications : October 24-28, 2004 : Vancouver Convention & Exhibition Centre, Vancouver, British Columbia, Canada$91916919 997 $aUNINA LEADER 03206nam 22006615 450 001 9910254184303321 005 20251230055143.0 010 $a3-319-23180-4 024 7 $a10.1007/978-3-319-23180-8 035 $a(CKB)3710000000467440 035 $a(EBL)4178528 035 $a(SSID)ssj0001546495 035 $a(PQKBManifestationID)16141307 035 $a(PQKBTitleCode)TC0001546495 035 $a(PQKBWorkID)14796391 035 $a(PQKB)11362427 035 $a(DE-He213)978-3-319-23180-8 035 $a(MiAaPQ)EBC4178528 035 $a(PPN)188459162 035 $a(EXLCZ)993710000000467440 100 $a20150817d2016 u| 0 101 0 $aeng 135 $aur|n|---||||| 181 $ctxt 182 $cc 183 $acr 200 10$aAdvanced and Intelligent Computations in Diagnosis and Control /$fedited by Zdzis?aw Kowalczuk 205 $a1st ed. 2016. 210 1$aCham :$cSpringer International Publishing :$cImprint: Springer,$d2016. 215 $a1 online resource (417 p.) 225 1 $aAdvances in Intelligent Systems and Computing,$x2194-5365 ;$v386 300 $aDescription based upon print version of record. 311 08$a3-319-23179-0 320 $aIncludes bibliographical references at the end of each chapters and index. 327 $aPart I Fault Detection and Isolation -- Part II Estimation and Identification -- Part III Robust and Fault Tolerant Control -- Part IV Industrial and Medical Diagnostics -- Part V Artificial Intelligence. 330 $aThis book is devoted to the demands of research and industrial centers for diagnostics, monitoring and decision making systems that result from the increasing complexity of automation and systems, the need to ensure the highest level of reliability and safety, and continuing research and the development of innovative approaches to fault diagnosis. The contributions combine domains of engineering knowledge for diagnosis, including detection, isolation, localization, identification, reconfiguration and fault-tolerant control. The book is divided into six parts:  (I) Fault Detection and Isolation; (II) Estimation and Identification; (III) Robust and Fault Tolerant Control; (IV) Industrial and Medical Diagnostics; (V) Artificial Intelligence; (VI) Expert and Computer Systems. 410 0$aAdvances in Intelligent Systems and Computing,$x2194-5365 ;$v386 606 $aComputational intelligence 606 $aArtificial intelligence 606 $aControl engineering 606 $aComputational Intelligence 606 $aArtificial Intelligence 606 $aControl and Systems Theory 615 0$aComputational intelligence. 615 0$aArtificial intelligence. 615 0$aControl engineering. 615 14$aComputational Intelligence. 615 24$aArtificial Intelligence. 615 24$aControl and Systems Theory. 676 $a610.28563 702 $aKowalczuk$b Zdzis?aw$4edt$4http://id.loc.gov/vocabulary/relators/edt 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910254184303321 996 $aAdvanced and Intelligent Computations in Diagnosis and Control$91539970 997 $aUNINA